Concurrent chemoradiotherapy for T3–4 and N0–1 nasopharyngeal cancer: Asian multicenter trial of the Forum for Nuclear Cooperation in Asia

Tatsuya Ohno1, Masaru Wakatsuki2*, Dang Huy Quoc Thinh3, Ngo Thanh Tung4, Dyah Erawati5, Nana Supriana6, C.R. Beena Devi7, Shingo Kato8, Kullathorn Thephamongkhol9, Yaowalak Chansilpa9, Miriam Joy C. Calaguas10, Xu Xiaoting11, Cao Jianping11, Parvin Akhter Banu12, Chul-Koo Cho13, Kumiko Karasawa2, Takashi Nakano14 and Hirohiko Tsujii2

1Gunma University Heavy Ion Medical Center, Gunma University, Gunma, Japan
2Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan
3Department of Radiation Oncology No. 3, Ho Chi Minh City Cancer Center, Ho Chi Minh City, Vietnam
4Head and Neck Radiation Department, National Cancer Hospital, Hanoi, Vietnam
5Department of Radiotherapy, Dr Soetomo General Hospital, Surabaya, Indonesia
6Department of Radiotherapy, Dr Cipto Mangunkusumo General Hospital, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia
7Department of Radiation Oncology, Sarawak General Hospital, Kuching, Malaysia
8Department of Radiation Oncology, Saitama Medical University International Medical Center, Saitama, Japan
9Department of Radiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
10Department of Radiation Oncology, St Luke’s Medical Center, Quezon City, Philippines
11Department of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China
12Department of Radiation Oncology, Delta Hospitals Limited, Dhaka, Bangladesh
13Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
14Department of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan

*Corresponding author. Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan. Tel: +81-43-206-3306; Fax: +81-43-256-6506; Email: masaru.wakatsuki@nifty.com

Received March 26, 2015; Revised May 18, 2015; Accepted June 16, 2015

ABSTRACT

The aim of this study was to evaluate the toxicity and efficacy of radiotherapy concurrent with weekly cisplatin for T3–4 and N0–1 nasopharyngeal cancer. Between 2005 and 2010, 70 patients with nasopharyngeal cancer (T3–4 N0–1 M0, World Health Organization Type 2–3) from Vietnam, Indonesia, Malaysia and Thailand were registered. Patients were treated with 2D radiotherapy concurrent with weekly cisplatin (30 mg/m²). Neither adjuvant nor induction chemotherapy was given. Ninety-three percent of the patients completed at least four cycles of weekly cisplatin during radiotherapy. The median total doses for the primary tumor and positive lymph nodes were 70 and 66 Gy, respectively. The median overall treatment time of concurrent chemoradiotherapy was 52 days. No treatment-related deaths occurred. Grade 3–4 acute toxicities of mucositis, nausea/vomiting and leukopenia were observed in 34%, 4% and 4% of patients, respectively. With a median follow-up time of 52 months for the 40 surviving patients, the 3-year local control, locoregional tumor control, distant metastasis-free survival and overall survival rates were 80%, 75%, 74% and 80%, respectively. In conclusion, the current results illustrate that our concurrent chemoradiotherapy regimen was feasible, but disease control remained insufficient. Further research is encouraged in order to improve clinical outcomes.

KEYWORDS: nasopharyngeal cancer, chemoradiotherapy, cisplatin, 2-dimensional radiotherapy, developing country
INTRODUCTION

Nasopharyngeal cancer (NPC) is a special type of head and neck cancer usually found in South and Southeast Asian and North African populations. Radiotherapy (RT) is the mainstay treatment for NPC because of its surgically inaccessible anatomic location and radiosensitive character. Several randomized clinical trials and meta-analyses have demonstrated that concurrent chemoradiotherapy (CCRT) is the most efficacious approach for locoregionally advanced NPC [1–4].

It is important to identify patient subgroups likely to develop local failure or distant metastasis in order to establish individualized cancer treatment plans. Chua et al. reported 5-year local control (LC) and distant metastasis–free survival (DMFS) rates of 70% and 85%, respectively, for the T3–4 and N0–1 groups, 79% and 70%, respectively, for the T1–2 and N2–3 groups, and 76% and 60%, respectively, for the T3–4 and N2–3 groups. From these analyses of the failure pattern of NPC before the chemotherapy era, advanced local disease (T3–4) tended to be associated with local failure, whereas advanced nodal disease (N2–3) tended to be associated with distant metastasis [5, 6]. For the latter patient group with advanced nodal disease (any T and N2–3), we first conducted a prospective study of CCRT and adjuvant chemotherapy. We reported that the 3-year locoregional control (LRC), DMFS and overall survival (OS) rates were 89%, 74% and 66%, respectively, for 121 patients registered from Vietnam, Malaysia, Indonesia, Thailand, the Philippines, China and Bangladesh [7]. In contrast, for patients with advanced local disease (T3–4 and N0–1), it is unknown whether induction or adjuvant chemotherapy is necessary. Therefore, as a second clinical study, we initiated a prospective study of CCRT without induction or adjuvant chemotherapy in this patient group. The purpose of this study was to evaluate the efficacy and toxicities of this regimen, especially in Southeast Asian countries, including Vietnam, Indonesia, Malaysia and Thailand, where NPC is endemic.

MATERIALS AND METHODS

This study was conducted within the Forum for Nuclear Cooperation in Asia (FNCA), a framework of regional cooperation among Asian countries supported by the Japanese government with the aim of peaceful and safe application of nuclear science and technology. The medical project of the FNCA was launched in 1993, aiming to standardize RT and CCRT for common cancers in Asia such as cervical cancer and NPC, with the participation of 11 Asian countries: Bangladesh, China, Indonesia, Japan, Kazakhstan, Korea, Malaysia, Mongolia, the Philippines, Thailand and Vietnam [8].

Patient eligibility

A multi-institutional, prospective, single-arm study was designed. Patients fulfilling all the following criteria were eligible for this study: histologically confirmed World Health Organization (WHO) Type 2 or 3 carcinoma of the nasopharynx, Stage III or IVA disease with T3–4 and N0–1 classification (UICC-TNM, 6th edition), age between 20 and 70 years, performance status (PS) 0–2, adequate bone marrow, hepatic, and renal function (WBC count ≥ 3000/mm³, Hb ≥ 10 g/dl, platelets ≥ 100 000/mm³, total bilirubin ≤ 1.5 mg/dl, AST/ALT ≤ 2x upper limit of normal, serum creatinine ≤ 1.5 mg/dl). The exclusion criteria were WHO Type 1 carcinoma of the nasopharynx, severe concomitant illness such as uncontrolled cardiovascular disease, uncontrolled diabetes mellitus, active peptic ulcer, severe infection, severe psychological illness, an active double cancer, prior RT or chemotherapy, and pregnancy or lactation. Written informed consent was obtained from all patients. All patients underwent nasopharyngoscopy and biopsy to obtain specimens for pathological diagnosis. Pretreatment evaluations included physical examination of the head and neck, computed tomography (CT), chest radiography, a complete blood cell count with differential counts, and a biochemistry profile. Because of differences in the availability of medical resources among the participating institutes, abdominal ultrasonography and bone scans were used optionally, but their use was recommended if possible.

Radiotherapy

Patients were treated using a 6- or 10-MV linear accelerator or a telecobalt unit via a conventional 2D-RT technique. The use of CT, magnetic resonance imaging (MRI), and nasopharyngoscopy is recommended to define the gross tumor. The superior margin of the initial radiation field ranged 2 cm beyond the visible tumor on CT and included the entire base of the skull and the sphenoid sinus. Posteriorly, the field extended at least 1.5 cm beyond palpable nodes. Anteriorly, the field included the posterior ethmoidal sinus, the posterior one-third of the maxillary antrum, or at least 1.5 cm beyond the visible tumor. Patients received conventional fractionalized RT (1.8–2 Gy per fraction, five daily fractions per week). Patients were treated in a supine position, usually with bilateral parallel opposing fields to the primary tumor and upper neck and a single anterior field to the lower neck with a central shield. After 40–45 Gy of radiation was delivered, the primary tumor was boosted using bilaterally opposed reduced portals. The bulky nodal area was irradiated with posterior–anterior parallel opposing ports for the neck region or an electron beam with appropriate energy. The total planned dose was 66–70 Gy for T3 lesions, 66–75 Gy for T4 lesions, and 60–70 Gy for the positive neck region. RT was suspended if a patient developed Grade 4 hematological toxicities, Grade 4 radiation mucositis of the oral cavity or pharynx, Grade 4 radiation dermatitis, ≥ Grade 3 non-hematological toxicities (e.g. nausea, vomiting) excluding mucositis and/or dermatitis, or PS 3–4. RT was resumed when the hematological and non-hematological toxicities recovered to Grade 2.

Chemotherapy

Cisplatin at a dose of 30 mg/m² was administered weekly starting from Week 1 for six consecutive weeks during the course of RT. Patients were hydrated with more than 1500 ml of normal saline per session. As antiemetics, 5-HT3 receptor antagonists and dexamethasone were given with the chemotherapy. The administration of cisplatin with RT was interrupted when patients developed a WBC count < 3000/mm³, a platelet count < 75 000/mm³, fever > 38.0°C, or PS 3–4, ≥ Grade 3 non-hematological toxicities (e.g. emesis, loss of appetite, fatigue), or serum creatinine > 1.5 mg/dl.

Assessment and follow-up

While patients were undergoing CCRT, toxicity and tumor response were evaluated weekly. The Common Terminology Criteria for Adverse Events v3.0 was used to evaluate toxicities. After treatment, follow-up examinations were conducted at least every 3 months for the initial 3 years and then every 3–6 months for the subsequent...
2 years. Disease status and toxicities were assessed by physical examination, appropriate laboratory tests, and chest radiography. Imaging modalities such as ultrasonography, CT or MRI were used if necessary. The LC, LRC, DMFS and OS rates were estimated using the Kaplan–Meier method. An annual meeting was held to review the patients’ eligibility, treatment technique employed in the study, toxicities and follow-up status in each center.

Statistical analysis
The primary endpoint of the study was the 3-year OS rate. The secondary endpoints included the 3-year LC rate, 3-year LRC rate, 3-year DMFS rate, acute toxicities and late toxicities. Based on the retrospective analysis of clinical data among the participating institutes of the FNCA project, the 3-year OS rate with 2D-RT alone for patients with locoregionally advanced NPC was 60%. The sample size evaluated in this study, which was calculated using the 3-year OS rate, was determined to be 100 patients. We chose a rate of 80% as a desirable target level and a rate of 60% as undesirable. Our design had a power in excess of 80% and a Type I error of less than 5%. Considering a decrease in power (e.g. loss to follow-up and entry of ineligible cases), this trial was designed to enroll 100 patients. The actual LC, LRC, DMFS and OS rates were calculated using the Kaplan–Meier method.

RESULTS
Patient characteristics
Between April 2005 and May 2010, 70 patients were enrolled from Ho Chi Minh City Cancer Center (Vietnam), National Cancer Hospital (Vietnam), Sarawak General Hospital (Malaysia) and Siriraj Hospital (Thailand). However, no new patient has been enrolled since May 2010, mainly because of competing clinical trials for NPC at each center and the relatively lower incidence of the disease. Following a discussion at the FNCA Workshop on Radiation Oncology in November 2013, enrollment in the current clinical trial was discontinued prematurely. Analysis was performed on all data entered at the FNCA data center as of 30 October 2013. The median follow-up period was 49 months for all patients, versus 52 months for the 40 surviving patients. The patient characteristics are listed in Table 1.

Treatment and compliance
A total of 39 patients (56%) were treated with the linear accelerator, and 31 patients (44%) were treated with a telecobalt unit. The median total doses for the primary tumor and positive lymph nodes were 70 and 66 Gy, respectively. The median overall treatment time of CCRT was 52 days. Of the 70 patients, 15 (21%) required interruption of RT. Five patients (10%) required interruption for more than 14 days, with the median duration of interruption being 7 days. The reasons for interruption of RT were acute non-hematological toxicities such as mucositis, pain and dermatitis in five patients, hematological and non-hematological toxicities in three patients, machine malfunction in three patients, and others (e.g. public holiday) in four patients. Of the 70 patients, 52 (74%), 10 (14%), 4 (6%) and 4 (6%) patients received 6, 5, 4 and 1–3 cycles of concurrent chemotherapy, respectively. The reasons for incomplete concurrent chemotherapy were treatment-related toxicities in 17 patients, patient refusal in 4 patients, and poor general condition in 1 patient.

Toxicities and efficacy
The hematological and non-hematological acute toxicities are listed in Table 2 and 3. One patient developed Grade 4 nausea/vomiting and anemia. The incidences of ≥Grade 3 mucositis, nausea/vomiting and leucopenia were 25.7%, 1.4% and 4.3%, respectively. The late

Table 1. Patient characteristics (n = 70)

| Characteristic       | Value  |
|----------------------|--------|
| Age (years)          | Median (range) 49 (27–65) |
| Gender               | Male 55 (79) |
|                      | Female 15 (21) |
| Performance status   | 0 21 (30) |
|                      | 1 35 (50) |
|                      | 2 14 (20) |
| T classification     | T3 41 (59) |
|                      | T4 29 (41) |
| N classification     | N0 15 (21) |
|                      | N1 55 (79) |
| Clinical stage       | Stage III 41 (59) |
|                      | Stage IVA 29 (41) |
| WHO classification   | Type 2 8 (11) |
|                      | Type 3 62 (89) |

Table 2. Hematological acute toxicities

| Toxicity         | Grade (CTCAE ver. 4) |
|------------------|----------------------|
|                  | 0 1 2 3 4            |
| Leukopenia       | 25 19 23 3 0         |
| Neutropenia      | 34 22 9 5 0          |
| Anemia           | 35 26 7 1 1          |
| Thrombocytopenia | 47 19 4 0 0          |
The incidences of ≥Grade 3 skin toxicity and dry mouth were 13% and 63%, respectively. The first sites of failure were locoregional sites in 21 patients, distant sites in 9 patients, and both locoregional and distant sites in 4 patients. Among the 25 patients with locoregional failure, the first failure sites were the primary lesion, lymph nodes and both in 14, 8 and 3 patients, respectively. The 3-year LC and LRC rates for all 70 patients were 80% and 75%, respectively (Fig. 1). The 3-year DMFS and OS rates for all 70 patients were 74% and 80%, respectively (Fig. 2).

**DISCUSSION**

In the present study, CCRT without induction or adjuvant chemotherapy was administered to patients with NPC (T3–4, N0–1) in Southeast Asian centers. The 3-year OS rate of 80% was relatively better than that of our historical control (60%; RT alone), but lower than recent published data in leading Asian facilities (85–90%; intensity-modulated radiation therapy [IMRT] with or without chemotherapy) [9]. Several points need to be considered when interpreting the clinical outcomes in this study. First, the target disease focused on a select disease category (T3–4 and N0–1) that is an uncommon form of NPC. Second, these clinical data were obtained mainly from Vietnam, Indonesia and Malaysia, where the English literature on CCRT for NPC is extremely limited, despite the high incidence of NPC [10]. Third, in the regions studied, most patients present with advanced disease, and the number of patients requiring RT generally exceeds the limited medical resources.

The present study suggested that T3–4 primary tumors were not sufficiently controlled by concurrent weekly cisplatin and 2D-RT. One possible reason is that compared with reports on IMRT, the 2D-RT technique used in our study contributed to inferior tumor control because IMRT could improve target coverage and normal tissue sparing. Su et al. reported 5-year LRC, DMFS and OS rates for patients with T3–4 and N0–1 NPC who were treated with IMRT with or without chemotherapy of 87%, 84% and 80%, respectively, which were relatively better than our outcomes [11]. Recently, other studies on IMRT also reported LRC rates of 81–96% for T3–4 tumors [12–14]. Additionally, a Phase III study illustrated the superiority of IMRT over 2D-RT in terms of LRC, OS and late toxicities [15]. Unfortunately, IMRT was not available in all participating centers during the study period, and the primary curative treatment mainly relied on 2D-RT.

The other possible reason for unfavorable LC was that the dose for the primary tumor (median dose, 70 Gy) in our study was insufficient. Teo et al. investigated the effect of dose escalation above a conventional tumor dose level of 66 Gy when the basic RT course was delivered by 2D-RT [16]. For T3–4 tumors, the administration of boost radiation, mainly with 2D-RT, (the median dose, 10 Gy) after 66 Gy significantly improved local tumor control. Increasing the dose for the primary tumor site appears promising; however, dose escalation with 2D-RT also increases the risk of late toxicities such as chronic radiation necrosis, hearing loss, dysphagia and temporal lobe toxicities are listed in Table 4. The incidences of ≥Grade 3 skin toxicity and dry mouth were 13% and 63%, respectively.

**Table 3. Non-hematological acute toxicities**

| Toxicity          | Grade (RTOG/EORTC) |
|-------------------|--------------------|
|                   | 0  | 1  | 2  | 3  | 4  |
| Dermatitis        | 4  | 32 | 27 | 7  | 0  |
| Mucositis         | 2  | 25 | 25 | 18 | 0  |
| Pain              | 9  | 35 | 21 | 5  | 0  |
| Dry mouth         | 3  | 31 | 34 | 2  | 0  |
| Nausea/Vomiting   | 21 | 37 | 11 | 0  | 1  |
| Weight loss       | 24 | 21 | 22 | 3  | 0  |
| Fatigue           | 26 | 18 | 24 | 1  | 1  |

**Table 4. Late toxicities**

| Toxicity          | Grade (RTOG/EORTC) |
|-------------------|--------------------|
|                   | 0  | 1  | 2  | 3  | 4  |
| Subcutaneous      | 8  | 33 | 29 | 0  | 0  |
| Mucosa            | 4  | 55 | 11 | 0  | 0  |
| Skin              | 6  | 31 | 24 | 9  | 0  |
| Dry mouth         | 0  | 12 | 14 | 44 | 0  |

**Fig. 1. Local control (LC) and locoregional control (LRC) rates for all 70 patients.**

**Fig. 2. Overall survival (OS) and distant metastasis-free survival (DMFS) rates for all 70 patients.**
necrosis. Kwong et al. reported that an IMRT dose of 76 Gy for T3–4 tumors in combination with cisplatin-based chemotherapy was associated with a 2-year LC rate of 96%, but 84% of the patients developed Grade 3 ototoxicity [12]. Several attempts have been made regarding dose escalation using 3D conformal techniques, stereotactic RT, and IMRT [9]; however, there is no standardized RT technique including the dose and fractionation schedule.

Our study indicated that CCRT alone for patients with T3–4 and N0–1 tumors was not adequate to control distant metastasis. In particular, because of the insufficient LRC, our data included secondary metastasis after locoregional failure. Thus, efforts should be made to minimize locoregional recurrence. In contrast, an increased possibility of distant failure was noted when the tumor invaded the bone marrow of the skull base or parapharyngeal venous plexus [17]. Su et al. observed similar DMFS rates between advanced local disease (T3–4 and N0–1) and advanced nodal disease (T1–2 and N2–3) groups [11]. To reduce systemic failure and improve survival, the combination of CCRT with induction or adjuvant chemotherapy has been also investigated. A recent Phase III randomized clinical trial comparing CCRT alone with CCRT and adjuvant chemotherapy in patients with locoregionally advanced NPC indicated that adjuvant chemotherapy consisting of cisplatin and 5-FU added little survival benefit to CCRT [13]. Additionally, two recent meta-analyses demonstrated that adjuvant chemotherapy after CCRT did not confer a statistically significant survival improvement compared with RT alone or CCRT [4, 18]. In contrast, the additional benefit of induction chemotherapy to CCRT for locally advanced NPC remains unclear. Fountzilas et al. reported a randomized Phase II study demonstrating that three cycles of induction chemotherapy followed by CCRT did not provide a significant survival benefit compared with CCRT alone [19]. Ongoing Phase III randomized trials will further explain the role of induction chemotherapy in combination with CCRT.

Our treatment regimen was feasible with manageable toxicities. When we consider an increase in the treatment intensity, however, care should be exercised because dose escalation or the addition of chemotherapy to CCRT will increase the risk of treatment-related toxicities. In developing countries in particular, the general conditions of the patients are compromised, and they could become further affected by RT machine malfunction (36%), patients’ poor condition (21%), and public holidays (14%) [22]. A similar survey was also conducted in Taiwan [23]. The mean diagnosis-to-treatment interval for RT was not measured. As the participating centers in the present study also had similar diagnosis-to-treatment intervals for RT, cancer might progress during the waiting time, resulting in more advanced disease.

In summary, 2D-RT concurrent with weekly cisplatin in patients with T3–4 and N0–1 NPC was feasible with manageable toxicities in the participating centers. However, the treatment regimen appeared insufficient for controlling both locoregional and distant disease. Further research is encouraged in order to improve clinical outcomes, especially focusing on the combination of high-precision RT modalities such as IMRT with systemic chemotherapy. Whereas, our clinical trial was divided between advanced nodal disease (N2–3) and advanced local disease (T3–4 and N0–1) groups, this protocol was conducted for patients with advanced local disease (T3–4 and N0–1). On the other hand, we first conducted a prospective study of CCRT and adjuvant chemotherapy for patients with advanced nodal disease (N2–3). In addition, we are now conducting a new clinical trial for patients with advanced nodal disease (N2–3) using induction chemotherapy followed by concurrent chemoradiotherapy.

ACKNOWLEDGEMENTS

The authors thank the staff members of the Japan Atomic Industrial Forums (JAIF) Inc. and the Nuclear Safety Research Association (NSRA) for organizing a series of FNCA Workshops on Radiation Oncology. Pittaya Dankulchai, Conchitina Mendoza, Sheila Gonzales, Tomoko Takahashi and Michiko Yoshino are thanked for their assistance with data collection. We are grateful to Tang Tieng Swee, Nguyen Chan Hung and Nguyen Ba Duc for their support of this work.

FUNDING

This work was supported by the project of The Forum Nuclear Cooperation in Asia (FNCA), the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan, and the research project of the National Institute of Radiological Sciences, Japan. Funding to pay the Open Access publication charges for this article was provided by the research project of the National Institute of Radiological Sciences, Japan.

REFERENCES

1. Thephemongkhol K, Zhou J, Browman G, et al. Chemo-radiotherapy versus radiotherapy alone for nasopharyngeal carcinoma: a meta-analysis of 78 randomized controlled trials (RCTs) from English and non-English databases. J Clin Oncol 2004;22:5522.
2. Langendijk JA, Leemans CR, Bouter J, et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 2004;22:4604–12.
3. Bajua B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006;64:47–56.
4. Zhang L, Zhao C, Ghimire B, et al. The role of concurrent chemo-radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase III randomized trials. BMC Cancer 2010;10:e558.
5. Chua DT, Sham JS, Wei WL, et al. The predictive value of the 1997 American Joint Committee on Cancer stage classification in determining failure patterns in nasopharyngeal carcinoma. Cancer 2001;92:2843–55.
6. Chua DT, Sham JS, Kwong DL, et al. Treatment outcome after radiotherapy alone for patients with Stage I–II nasopharyngeal carcinoma. *Cancer* 2003;98:74–80.

7. Ohno T, Thinh DH, Kato S, et al. Radiotherapy concurrently with weekly cisplatin, followed by adjuvant chemotherapy, for N2–3 nasopharyngeal cancer: a multicenter trial of the Forum for Nuclear Cooperation in Asia. *J Radiat Res* 2013;54:467–73.

8. Kato S, Ohno T, Thephamongkhol K, et al. Long-term follow-up results of a multi-institutional phase 2 study of concurrent chemoradiation therapy for locally advanced cervical cancer in east and southeast Asia. *Int J Radiat Oncol Biol Phys* 2013;87:100–5.

9. Kam MKM, Wong FCS, Kwong DLW, et al. Current controversies in radiotherapy for nasopharyngeal carcinoma (NPC). *Oral Oncol* 2014;50:907–12.

10. Devi BCR, Pisani P, Tang TS, et al. High incidence of nasopharyngeal carcinoma in native people of Sarawak, Borneo Island. *Cancer Epidemiol Biomarkers Prev* 2004;13:482–6.

11. Su SF, Han F, Zhao C, et al. Treatment outcomes for different subgroups of nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy. *Chin J Cancer* 2011;30:565–73.

12. Kwong DL, Sham JS, Leung LH, et al. Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* 2006;64:374–81.

13. Chen L, Liu LZ, Chen M, et al. Prognostic value of subclassification using MRI in the T4 classification nasopharyngeal carcinoma intensity-modulated radiotherapy treatment. *Int J Radiat Oncol Biol Phys* 2012;84:196–202.

14. Chen JLY, Huang YS, Kuo SH, et al. Intensity-modulated radiation therapy for T4 nasopharyngeal carcinoma: treatment results and locoregional recurrence. *Strahlenther Onkol* 2013;189:1001–8.

15. Peng G, Wang T, Yang KY, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. *Radiother Oncol* 2012;104:286–93.

16. Teo PM, Leung SF, Tung SY, et al. Dose–response relationship of nasopharyngeal carcinoma above conventional tumoricidal level: a study by the Hong Kong nasopharyngeal carcinoma study group (HKNPCSG). *Radiother Oncol* 2006;79:27–33.

17. Cheng SH, Tsai SY, Yen KL, et al. Prognostic significance of parapharyngeal space venous plexus and marrow involvement: potential landmarks of dissemination for stage I–III nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* 2005;61:456–65.

18. OuYang PY, Xie C, Mao YP, et al. Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, controlled trials. *Ann Oncol* 2013;24:2136–46.

19. Fountzilas G, Ciuleanu E, Bobos M, et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. *Ann Oncol* 2012;23:427–35.

20. Vikram B. Cancers of the head and neck region in developing countries. *Radiother Oncol* 2003;67:1–2.

21. Shashinder S, Choo PK, Gopala KG. Outcome of patients with head and neck cancers: 10-year experience of a otorhinolaryngology – head and neck unit in a tertiary hospital of a developing country. *Eur J Cancer Care* 2008;17:93–7.

22. Stoker SD, Wildeman MA, Fles R, et al. A prospective study: current problems in radiotherapy for nasopharyngeal carcinoma in Yogyakarta, Indonesia. *PLoS ONE* 2014;9:e85959.

23. Chen PC, Yang CC, Wu CJ, et al. Factors predict prolonged wait time and longer duration of radiotherapy in patients with nasopharyngeal carcinoma: a multilevel analysis. *PLoS ONE* 2014;9:e109930.